Recombinant gp160 as a therapeutic vaccine for HIV-infection: results of a large randomized, controlled trial.

OBJECTIVES: The primary objective of this study was to expand the safety and immunogenicity database of recombinant gp160 as a therapeutic vaccine in the treatment of HIV-infection. Preliminary efficacy data was also sought. DESIGN: This trial was a randomized, double-blind, placebo-controlled study. Two-hundred and eight volunteers, 96 therapy-naive with CD4 cell count >500x10(6)/l (group A) and 112 with CD4 cell count of 200-500x10(6)/l (group B, 51 out of 112 on treatment with one or two nucleoside analogues), received monthly injections of rgp160 IIIB vaccine or placebo for the first 6 months of the study; booster immunizations with rgp160 MN or placebo were given at times 15, 18, and 21 months. METHODS: Safety and immunogenicity data were obtained and measurements of CD4 cell count, plasma viral RNA, and proviral DNA were performed. Clinical outcome was recorded for the 24 months of study. RESULTS: The vaccine was safe and well tolerated. Despite the induction of new rgp160-specific lymphoproliferative responses and the presence of positive delayed type hypersensitivity skin tests to rgp160 at the end of the 24 month study, no effect on the natural history of HIV infection was detected. Within 24 months, AIDS-defining illnesses had occurred in 19 of the vaccinated volunteers and in 18 of the placebo recipients. Persons with higher plasma viral RNA levels and higher proviral DNA had a more rapid decline in CD4 cell count when compared to persons with lower values. Vaccine did not alter viral RNA or proviral DNA levels. CONCLUSION: There was no clinical benefit to therapeutic immunizations with rgp160, despite the induction of new lymphoproliferative responses. &nbsp

The Production of Polyclonal Antibodies in Laboratory Animals

This is the report of the thirty-fifth of a series of workshops organised by the European Centre for the Validation of Alternative Methods (ECVAM). ECVAM\u27s main goal, as defined in 1993 by its Scientific Advisory Committee, is to promote the scientific and regulatory acceptance of alternative methods which are of importance to the biosciences and which reduce, refine or replace the use of laboratory animals. One of the first priorities set by ECVAM was the implementation of procedures which would enable it to become well-informed about the state-of-the-art of non-animal test development and validation, and the potential for the possible incorporation of alternative tests into regulatory procedures. It was decided that this would be best achieved by the organisation of ECVAM workshops on specific topics, at which small groups of invited experts would review the current status of various types of in vitro tests and their potential uses, and make recommendations about the best ways forward (1)

Produção de citocinas e óxido nítrico por macrófagos de camundongos infectados com flavivírus brasileiros

The Flaviviridae family, Flavivirus genus includes viruses that are transmitted to vertebrates by infected mosquitoes or ticks. The genus Flavivirus includes a variety of viruses that cause diseases such as acute febrile illness, encephalitis, and hemorrhagic fever. Flaviviruses primarily infect blood monocytes and tissue macrophages, which have been shown to be permissive, supporting viral replication and serving as virus reservoirs. On the other hand, these cells may have an important antiviral activity related to modulation by cytokine production and by the capacity of these cells to synthesize reactive free radicals such as nitric oxide (NO) which can have a microbicidal effect. The present study was performed in order to determine the production of cytokines interleukin-1beta (IL-1β), tumor necrosis factor -alpha (TNF-α), transforming growth factor- beta (TGF-β) and interferon -alpha (IFN-α) and NO by macrophages infected with one of four Brazilian flaviviruses, Bussuquara virus (BUSV), Yellow Fever virus (YFV), Rocio virus (ROCV) and Encephalitis Saint Louis virus (SLEV), and to verify the possible antiviral effect of NO during macrophage infection with ROCV. Moreover, we asked if the different viruses were able to regulate bacterial lipopolysaccharide (LPS) induced cytokine production. Our results showed that YFV and SLEV reduced the production of IL-1β and TGF-β by LPS-stimulated macrophages, while ROCV only diminished LPS-stimulated TGF-β synthesis. On the other hand, BUSV more likely favored an enhancement of the LPS-induced production of IL-1β by macrophages. Additionally, while most of the viruses stimulated the production of IFN-α, none of them altered the production of TNF-α by murine macrophages. Interestingly, all viruses induced synthesis of NO that was not correlated with antiviral activity for ROCV.A família Flaviviridae, gênero flavivírus inclui vírus que são transmitidos para os vertebrados por mosquitos e carrapatos. O gênero flavivirus inclui uma variedade de vírus que causa doenças como febres, encefalites e febres hemorrágicas. Primeiramente, as flaviviroses infectam monócitos do sangue e macrófagos do tecido, o qual tem mostrado ser permissivo, suportando a replicação viral e servindo como reservatório de vírus. Por outro lado, essas células podem ter uma importante atividade antiviral relacionada à modulação pela produção de citocinas e pela capacidade destas células sintetizar reativos de radicais livres como óxido nítrico (NO) o qual tem efeito microbicida. O presente estudo foi realizado a fim de determinar a produção de citocinas interleucina -1 beta (IL-1β), fator de necrose tumoral-alfa (TNF-α), fator de crescimento transformador-beta (TGF-β), interferon - alfa (IFN-α) e NO pelos macrófagos infectados com os quatros flavivírus como vírus Bussuquara (BUSV), vírus da febre amarela (YFV), vírus Rocio (ROCV) e vírus da Encefalite de Saint Louis (SLEV), e verificar o possível efeito antiviral de NO durante a infecção dos macrófagos com ROCV. Além disso, com os diferentes vírus foram capazes de regular o lipopolissacarídeo bacteriano (LPS) indutor da produção de citocinas. Nossos resultados mostraram que YFV e SLEV reduziram a produção de IL-1β e TGF-β quando macrófagos foram estimulados pelo LPS, enquanto ROCV somente diminuiu a síntese de TGF-β estimulada pelo LPS. Entretanto, BUSV favoreceu uma acentuada produção de IL-1β pelos macrófagos estimulados pelo LPS, enquanto os vírus estimularam a produção de IFN-α, nenhum deles alterou a produção de TNF-α pelos macrófagos murinos. Interessantemente, todos os vírus induziram a síntese de NO que não esteve correlacionada com a atividade antiviral pelo ROCV